Siemens Healthineers Get FDA Nod for New SPECT/CT Scanner

The Food and Drug Administration (FDA) has granted 510(k) clearance to the Symbia Pro.specta™ SPECT/CT Scanner, according to Siemens Healthineers, the manufacturer of the device.

Launching the device at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, Siemens Healthineers said the single-photon emission computed tomography/computed tomography (SPECT/CT) system offers advanced imaging technology. Key benefits include automated SPECT motion correction and the ability to obtain up to 64 slices of low-dose CT to facilitate detailed image quality, according to the company.

In addition to optimal low-dose imaging, Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner offers myExam Companion, which provides automated workflow guidance. The company adds that clinicians will also have access to the device’s customized clinical tools designed to ensure optimal imaging with cardiology, neurology, oncology, and orthopedic applications.

Siemens Healthineers noted the Symbia Pro.specta™ SPECT/CT Scanner will offer improved accessibility, noting that it should fit in most existing SPECT rooms and is designed to replace the Symbia Intevo™ line of SPECT/CT scanners.

“Siemens Healthineers is proud to introduce the Symbia Pro.specta SPECT/CT scanner, which provides our customers with the ideal vehicle for transitioning from their SPECT-only and first-generation SPECT/CT cameras to a state-of-the-art SPECT/CT scanner that can perform a full spectrum of nuclear medicine examinations,” said Jim Williams, Ph.D., the head of Siemens Healthineers Molecular Imaging. “The Symbia Pro.specta will help health-care institutions overcome barriers to care by ensuring accessibility through its ease of use and ability to fit into existing SPECT rooms.”